Hansard·Westminster Hall·Vol. 793

Medicines and Healthcare Products Regulatory Agency

Tuesday, 17 November 2026

44 contributions17 members

Contributions

  1. Esther McVey (Tatton) (Con)Conservative

    I beg to move, That this House has considered the performance of the Medicines and Healthcare products Regulatory Agency. It is an honour to serve under your chairmanship, Sir John. I thank the Backbench Business Committee for granting today’s important debate, and the many colleagues from across the House who came together to support the application to the Committee. The Medicines and Healthcare products Regulatory Agency is the body responsible for ensuring the safety and efficacy of medicines and medical devices in the UK. That is a huge responsibility with the potential to change countless lives for the better, but also with the potential to cause great suffering and even death. We last came together to highlight serious and ongoing failures at the agency in a debate chosen by the Backbench Business Committee in January last year. Since then, I am afraid that we have seen little—if any—discernible improvement in its performance. Last time, we flagged worrying inadequacies in the yellow card reporting scheme, yet nothing has happened. We highlighted the lack of transparency in how the agency approves drugs and devices, and then monitors their safety—again, nothing has happened. We called on the Government to fully implement the recommendations in the 2020 Independent Medicines and Medical Devices Safety Review and to acknowledge the harm done to patients—yet again, nothing has happened. Those harmed by Primodos, sodium valproate and surgical mesh—some of whom are in the Public Gallery today—are still awaiting redress after campaigning for years and, in some cases, decades.

    View contribution permalink →

  2. Perran Moon (Camborne and Redruth) (Ind)Independent

    I have several constituents affected by the Primodos scandal. Six years on, after the Cumberlege review called for substantial reform of the MHRA, can we honestly say that patients feel more involved in decision making, and is there anything in the MHRA’s strategy 2030 that gives the right hon. Lady confidence that a future Primodos scandal would be handled differently?

    View contribution permalink →

  3. Esther McVeyConservative

    The hon. Member raises a very important point: this is a tragedy that has gone on for many years. I have to say that if we look at past performance, I have no confidence going forward. That is why I will ask to meet the Minister. Let us meet the MHRA to get the confidence that the hon. Member and his constituents need and want. I am pleased to see colleagues here today who will talk passionately—as he just did—on behalf of those who have suffered as a result of those medical scandals. I do not want to repeat the litany of serious concerns I raised in the debate last year. Instead, I want to use my time today to highlight a specific and tragic case that lays out the human cost of the MHRA’s utter incompetence. In spring 2022, an 80-year-old mother with advanced Alzheimer’s, who was living in a care home in my constituency, received the Moderna covid-19 vaccine booster. She became ill the following day with a very high fever, severe and repeated vomiting, and hypoactive delirium, which is very serious for those with dementia. She deteriorated rapidly and subsequently died. There were reports of mass serious adverse reactions in the same care home after the booster was given, and a second related death. Did the MHRA investigate? No. Did it respond fully to the family’s subsequent complaint? No. Did the MHRA review why the vaccine was approved for frail and elderly people, despite them being absent or under-represented in clinical trials? No. To quote from Moderna’s risk management plan, “frail subjects with unstable health conditions and co-morbidities”, including chronic neurological diseases, were identified as “Missing Information”. Why was the MHRA not honest about the woeful lack of safety evidence for using Moderna in the frail and elderly care home cohort? My constituent’s son and daughter have pulled together the most extraordinary dossier of evidence, not just about their mother’s case but the wider issues it highlights about how drugs are assessed and approved for the elderly, and how safety signals were ignored and dismissed. They have basically done the MHRA’s job for them. Their vaccine damage payment scheme application prompted an investigation that amassed 944 pages of detailed medical evidence. It resulted in a successful claim, but the MHRA has still done nothing. In July this year, the family lodged a formal complaint about the MHRA’s handling of their mother’s case. The all-party parliamentary group on pandemic response and recovery, which I co-chair with the hon. Member for Blackley and Middleton South (Graham Stringer), supported that complaint. To date, the family has still not had a reply to the complaint. The APPG did receive a reply from the Minister, though I am sorry to say it was inadequate, failing to mention the frail elderly, recognise the family’s vaccine damage payment scheme judgment or any consideration of the individual case. He was keen to reiterate that patient safety is the MHRA’s top priority, but those words mean nothing if they cannot be backed up with meaningful action. This case is not an isolated one. It exemplifies the problems that I and other Members have raised repeatedly. In February 2024, our APPG, together with more than two dozen cross-party colleagues, wrote to the Health and Social Care Committee urging a thorough, wide-ranging investigation into the MHRA. We described the agency as being at “the heart of…endemic failings” that continue to put patients at serious risk. Those failings include deficiencies in the yellow card scheme, inadequate post-marketing surveillance, conflicts of interest, lack of transparency and a failure to scrutinise and act promptly on data safety concerns. What happened to my constituent sadly aligns with those long-standing concerns. The MHRA did not properly evaluate or respond to the cluster of adverse events in that care home, where the residents were highly vulnerable. The MHRA seems happily to write off adverse reactions in the elderly as a mere temporal coincidence, yet the events in this case should have triggered rigorous investigation. Comorbidities, frailty, physiological decline and multiple medications mean that care home residents are more susceptible to adverse effects. The MHRA is supposed to uphold the guidelines in the good pharmacovigilance practices documents, which stress the importance of monitoring the elderly population, due to increased risk factors. We see no evidence of that in relation to this case. We will hear over the course of this debate how MHRA has failed many more patient groups, which have suffered life-changing injury or death due to other drugs or devices. I hope that will help to focus the Minister’s mind to act and find solutions. The human cost to patients and the financial burden on the healthcare system are substantial. Failure to act will lead only to more harm and further damage to public trust.

    View contribution permalink →

  4. Sir Christopher Chope (Christchurch) (Con)Conservative

    I congratulate my right hon. Friend on securing this timely debate. Is she going to refer to the report of module 4 of the covid inquiry that identified serious flaws with the yellow card system? Does she share my concern than the MHRA, as an independent regulator, fell down on its responsibilities during the covid pandemic, by refusing to acknowledge that the vaccines were not absolutely safe, as we now know, from the awards made under the compensation scheme? More than 200 cases of death or serious injury arising from covid-19 vaccines have been established, but the MHRA was in denial at the time when people needed the truth.

    View contribution permalink →

  5. Sir John Hayes (in the Chair)Conservative

    We hope we might hear from the hon. Gentleman at even greater length later.

    View contribution permalink →

  6. Esther McVeyConservative

    My hon. Friend has put that important point on the record; I know other people will speak to that today. It is yet another finding about the inadequacy of the agency. Finally, will the Minister for Health Innovation, who jointly launched and endorsed the MHRA strategy 2030 last month, attend the meeting that I have with the Minister for Public Health and Patient Safety, who has agreed to a meeting with me and the family of my former constituent? Or can he commit to a further meeting without delay? The performance of the MHRA in this case fell short of what we should expect. I feel sure the Minister will want to do the right thing and learn from that case to help to protect future patients from such devastating harm.

    View contribution permalink →

  7. Graham Stringer (Blackley and Middleton South) (Lab)Labour

    It is a pleasure to see you in the Chair, Sir John, and to follow the right hon. Member for Tatton (Esther McVey). We chair the all-party parliamentary group on pandemic response and recovery, which we set up after the pandemic, partly because, as the right hon. Member has just said, of failures during the pandemic. We wanted to investigate what was happening afterwards and make recommendations to improve the process. We were left confounded by trying to get information regularly from the MHRA, which is a very strange beast indeed. It is an arm’s length regulator, which is sensible, but it is funded by the pharmaceutical industry. That inevitably leads to a belief, and it seems to be the case in practice, that the MHRA is working not on behalf of the public and patients, but on behalf of the pharmaceutical industry. That is further exacerbated by its secretive ways. It has not responded in the past to freedom of information requests and has not responded adequately to our requests for further information about how it is proceeding, assessing and investigating yellow card complaints. So it leads me to ponder whether it should continue to exist. The questions asked by the hon. Member for Camborne and Redruth (Perran Moon) are the right questions: can it be improved? Will it reform itself? Can it be reformed by the Government and improve? From my experience over the last four or five years, it cannot. We therefore have to ask whether this regulatory quango would be best as an advisory body to the Secretary of State for Health and Social Care, because one problem we have had is getting information out of the MHRA. Although parliamentary democracy is imperfect and sometimes we have difficulties in getting information out of Departments, at least we can get the Secretary of State and the Minister on to the Floor of the House, in front of Select Committees and in debates in Westminster Hall to ask questions directly when things go wrong, which is not possible with the MHRA. So, I have come to the conclusion that there should be a serious investigation and assessment of the MHRA by the Government. Obviously, they would have to look at the evidence, but at the moment I think that they should bring it in as an advisory body. My answer to the question is that it is not reformable as it stands. I would like to take up one further, rather detailed point that the right hon. Member for Tatton made about her constituent, an elderly lady, who died. When the very quick—and, in the final analysis, effective—tests on the vaccines were carried out, as is often the case, elderly people were either not present or under-represented in those tests. That is not unreasonable in itself, but it means that the MHRA should spend more time looking at what has happened when there are adverse events and deaths following injections. Those people were not really tested when the vaccine itself was tested. But the MHRA has done completely the opposite: when there have been adverse events and deaths, it has effectively ignored them and not properly assessed and investigated them. There are a number of simple points I want to make, although there are people who want to speak. When I looked at the debate we had on 16 January last year, one thing I had forgotten that surprised me was that a number of hon. Members blamed the fact that we had left the European Union for the inadequacies of our regulation. That is the exact opposite of the truth. The fact is that by taking regulation in-house, we should have been able to be more effective. When the European Medicines Agency was in charge, we did not know who was regulating our medicines and devices, because those devices and medicines could be approved anywhere in Europe. I will finish with a number of questions, but before I get to them there is another case that has not been mentioned before. Voy has put adverts on London buses with the slogan “The Weight is Over”, which is a pun on waiting to get rid of excess weight. The MHRA and the Advertising Standards Agency have found it to be in breach of the regulations. We are not allowed by law in this country to advertise prescription medicines and this is clearly a device to get around that. The MHRA found against it, saying some very strong things in condemnation of those adverts, but what has been the consequence? Zero. It is great to criticise an illegal advert, as found by both regulatory bodies, but what has been the consequence for Voy? Even when the MHRA has assessed things, it has not really pursued it. I would like to finish with four questions. We do not know how much has been spent on the yellow card system. Will the Minister tell us that, or will he find out? How much is spent on the regulation on devices and medicines? We cannot find that out. How many individual investigations have there been, and how many have led to changes in advice on prescriptions? I would be grateful if the Minister could answer those questions either today or by correspondence.

    View contribution permalink →

  8. Sir John Hayes (in the Chair)Conservative

    The co-sponsors of the debate having spoken, I remind Members to bob if they wish to be called to speak. I see Sammy Wilson.

    View contribution permalink →

  9. Sammy Wilson (East Antrim) (DUP)Democratic Unionist Party

    Thank you, Sir John. The failures of the MHRA have been well documented. The speeches today have focused on the failure of covid vaccinations, but the failures go back a long time. They involve issues such as pelvic mesh—I can remember seeing a constituent whose life was destroyed by the insertion of pelvic mesh—as well as sodium valproate, breast implants, metal hip replacements and puberty blockers. The APPG on pandemic response and recovery, of which I am a member, has been focusing on covid vaccinations. Despite those failures being known, with a report having been made on them six years ago, no lessons appear to have been learned. The problems have been highlighted already this morning. First, we must question the independence of the MHRA. Is it independent financially? Half of its income comes from the pharmaceutical companies. Is it even independent politically? I sometimes wonder why the early signs of problems with the covid vaccine were not highlighted earlier. Was it because the Government were afraid that highlighting them may have made people wary of taking the vaccine? That is not a good reason. Some European countries had already identified problems with the AstraZeneca vaccine, yet it took six months for the MHRA to accept that there were problems with clotting and so on. The yellow card reporting mechanism has not worked. Only about 10% of serious cases, and 2% of non-serious cases, are highlighted. It may be that the system is too complicated, that doctors or patients do not know about it, or that there is not enough time to do the research, but if a reporting mechanism leads to only 10% of serious cases being highlighted, there must be something wrong with it. On transparency, the APPG on pandemic response and recovery has had difficulties in trying to get information. Even when we have asked pointed questions—not vague questions, but questions that there should have been answers to—there has been either no response or a delayed response. Another issue is the composition of the MHRA: patients are not represented properly on it. What kinds of reforms are required? First, there must be genuinely independent oversight. We cannot have a regulator that almost marks its own homework. Secondly, there should be mandatory reporting. When problems are highlighted, there should be a mechanism whereby doctors have to respond. If a patient comes in and highlights that they have taken a certain drug or vaccine and are having problems, there should be a mandatory reporting requirement.

    View contribution permalink →

  10. Mr Gregory Campbell (East Londonderry) (DUP)Democratic Unionist Party

    My right hon. Friend is outlining a plethora of issues that are at the heart of the MHRA. Does he agree that at the basis of this issue is the wider community’s total lack of confidence and trust in how effectively the MHRA conducts its work?

    View contribution permalink →

  11. Sammy WilsonDemocratic Unionist Party

    My hon. Friend is right; indeed, if the public were aware of the difficulties that there have been even in trying to get the results of investigations, they certainly would not have any confidence in the body to do its job properly. There should be mandatory reporting and, once problems have been reported, there must be evidence of proper investigation of those issues. Again, as highlighted by the proposer of the motion, sometimes we do not even know if the reports made about the impacts of the covid vaccine were properly investigated and what the outcomes were. There needs to be patient representation on the MHRA. I would like to ask the Minister three or four questions. First, why has it taken six years for the recommendations in Baroness Cumberlege’s report to be implemented and will he commit to having them implemented now? Secondly, will he introduce a system of mandatory reporting so that when issues are raised, they are not just buried, forgotten or left aside because there has not been sufficient time? Thirdly, what has changed in the MHRA’s handling of serious and fatal yellow card reports, and what investigation have the Government done into that? Lastly, what lessons has the MHRA learned from the original approval and subsequent notifications of its own pathway trial? It is important to have confidence in the work of the MHRA. Radical reforms are needed and those are some of the things I think need to be done.

    View contribution permalink →

  12. Mrs Sharon Hodgson (Washington and Gateshead South) (Lab)Labour

    It is a pleasure to serve under your chairmanship, Sir John. I thank the co-chairs of the all-party parliamentary group for calling this important debate and for bringing to light an issue that is vital to every aspect of patient safety. From mesh to Poly Implant Prothèse breast implants, and from thalidomide to sodium valproate, the MHRA has shown time and again that it needs a complete overhaul of its approval systems, which seem to leave transparency and patient safety at the door. We promised thalidomide victims back in 1973 that nothing like that scandal would every happen again, yet we have seen scandal after sandal since. After the thalidomide scandal came the sodium valproate scandal. The drug was approved for nationwide prescription just a year after thalidomide was banned. At the same time, the forerunner to the MHRA decided it was best not to mention the adverse effects of sodium valproate on animal foetuses as it would give way to “fruitless anxiety”. That “fruitless anxiety” meant the campaigners for foetal valproate syndrome, who we all know well—Janet Williams and Emma Murphy—were dismissed by the MHRA. The MHRA is at the heart of the epidemic of medical scandals and, quite frankly, like the right hon. Member for Tatton (Esther McVey), I have had enough. The Government urgently need to launch an inquiry to put an end to the chain of scandals before there is more harm on the MHRA’s hands. The MHRA’s priority needs to be no longer just risk minimisation, but risk prevention. The pharmaceutical company that produced sodium valproate issued warnings about the teratogenic nature of the product. The forerunner to the MHRA shamefully decided to ignore those warnings and not disclose them to patients. As another example of harm—of which there are so many—as recently as 2017, the director of medical devices at the MHRA explained that using mesh during surgery was perfectly safe based on its evidence. Weeks later, the Food and Drug Administration in the USA banned the use of vaginal prolapse mesh due to the harm it was causing women. The wonderful Baroness Cumberlege, who so many of us worked with on her excellent report, paused sling mesh surgery for incontinence just a year later.

    View contribution permalink →

  13. Jim Shannon (Strangford) (DUP)Democratic Unionist Party

    The hon. Lady has referred clearly to the issue of mesh that was passed as okay here, and told us what the USA did within weeks of that statement from the MHRA. Is there not an onus on the UK health service and those across the world? If they had known in advance what would happen in the USA, the use of mesh would never have been agreed to.

    View contribution permalink →

  14. Mrs HodgsonLabour

    I agree that there are lessons to be learned from across the world. If one country is looking at the harm that some drug or medical device is causing to patients, then the rest of the world should take notice, but there are so many examples where that just does not happen. In 2018, the MHRA confirmed three deaths associated with mesh incontinence procedures. That is the very same MHRA that in its “Strategy 2030” described itself as having an “overriding priority of patient safety.” As recently as last night, at a reception on the Terrace in Parliament, I listened to speeches by the senior people at the MHRA and had conversations with people working there about how patient safety is at the centre of everything that they do. That might indeed be the MHRA’s genuine ambition now, but we cannot forget the failures of the very recent past: there are women and children today living with the consequences of its failures. Where was patient safety as recently as 2017, when it deemed that mesh was safe for use in surgery despite its harms already being public knowledge? It seems to me, and maybe to all of us here today, that patient safety is not always the overriding priority that it should be for the MHRA. Patient safety also seems to be forgotten when it comes to financial conflicts of interest. During the covid-19 vaccine roll-out, several experts on the advisory committee had undisclosed financial ties to the vaccine companies. There are current reports of hernia mesh surgeons receiving undisclosed financial donations from mesh suppliers. Even since the complications of using plastic mesh were brought to light, it has often been reported that there is a revolving door between those working for the MHRA—the independent regulator—and those working in the industry. What guardrails are in place, such as there are for Government, Ministers and Parliament, to ensure that transparency and patient safety are paramount? MPs have to disclose everything that might give rise to a conflict of interest, but in the medical profession, with medical devices and drugs, that is not the case. In my opinion that is wrong. I heard last night that the MHRA is launching a new programme to tackle gaps in women’s health—something that I and, I am sure, many of us here today would welcome. However, in the past, the MHRA has failed women, with little remedy and, as far as I am aware, not even an apology. As we heard from the right hon. Member for Tatton, the yellow card reporting system has been known to capture only a fraction of medicinal side effects and medical device complications. After the Cumberlege review, the medical devices outcomes registry was set up in 2024 as an avenue for medical device performance to be reviewed by healthcare professionals, with the intention of linking the registry to the MHRA’s current data. Two years later, MDOR still has not been associated with the MHRA’s yellow card system, leaving medical devices unbeknown to the scrutiny of the regulator. If the MHRA is failing its audits on existing treatment outcomes, how will the women of tomorrow be reassured by the investment in women’s health that it launched yesterday? We promised victims of thalidomide decades ago that this would never happen again; we told victims of sodium valproate that we were very sorry that their children had been put through what they were put through; just three weeks ago at Prime Minister’s questions, the Prime Minister said from the Dispatch Box that he would ensure that there is justice for the victims of Primodos—another scandal that Baroness Cumberlege covered in her report—on his watch; and we assured the victims of mesh that they would be listened to and put first in conversations about patient safety. So why does this keep happening? What drug or medicinal device are we prescribing now that has been rushed through regulations without proper checks? When will enough be enough, and when will the MHRA finally be held accountable for its part in these scandals?

    View contribution permalink →

  15. Sorcha Eastwood (Lagan Valley) (Alliance)Alliance

    It is a pleasure to serve under your chairmanship, Sir John. I thank the right hon. Member for Tatton (Esther McVey) and the hon. Member for Blackley and Middleton South (Graham Stringer) for bringing this matter to the House today. I want to start today by referring to two incredible people, who became heroes of mine after I watched “Mums v Big Pharma” last week. I sat with my husband and watched it, and we ended it in tears. I know about sodium valproate, because over the years many of my constituents in Lagan Valley have raised it with me as an issue. I also know about pelvic and hernia mesh, for the same reason. But it is not until you see the damage that these products have wrought on families that it is really brought home. I want to get to the heart of an issue that I feel is critical in all this. Hon. Members from across the House have already said that they feel there is a barrier, and potentially a conflict of interest, and they have questioned the foundation of the MHRA itself and its status as an arm’s length body. I think there is something deeper going on. Whether it is sodium valproate, Primodos, thalidomide, mesh or one of many other things, there is an issue of class. That might be uncomfortable or controversial, but many people in this country trust the medical profession and regulatory authorities without question, to the extent that we have tried to bring in interventions such as the Hillsborough law so that there are barriers and systems to ensure that those bodies are beyond reproach. But if we expect members of the public to be the lone voice against pharmaceutical giants and we disregard them, where is the robustness in that system? I look at Emma Murphy and Janet Williams. They describe themselves, in our parlance in Northern Ireland, as two wee women. Well, I will tell you what: they are some women. They faced barriers and discrimination for years, and where did it leave us? Hundreds of thousands of families up and down the country have been impacted—damaged—unnecessarily. I look at the guardrails that Members across this House have raised many times, and I question their efficacy and effectiveness. Let me point out, too, that this has damaged everyone in society—men, women and children—but there is a particular issue around women’s health, and I find the issues raised by the hon. Member for Washington and Gateshead South (Mrs Hodgson) particularly concerning. I say to the House today that we have to stop this reverence. We have to listen to people. People have questioned how robust and effective the yellow card system is, but we do not empower people in this country; we tread on them. We close ranks—professional ranks and medical ranks—and we gaslight them. We tell them they are the problem. We hear about the “fruitless anxiety” that was mentioned in reports. We hear about not wanting to concern people. Meanwhile, we know that people are consuming a drug that we know to have teratogenic impacts. How disgusting, and how wrong. The final insult is that the redress promised to so many families across the UK is still outstanding. But this is not about the redress; it is about the fact that we have a system that is clearly not fit for purpose. We have to ensure that these regulatory bodies are indeed beyond reproach. It is not enough for links to be based on an old school tie, class references or anything else; we have to ensure that they are robust. I want to conclude by expressing my heartfelt thanks to the families up and down the country that have been failed by the MHRA and the state. They deserve nothing but our applause and adulation, but the applause is meaningless unless we change this absolutely wrong system, which has damaged people and left many of us in this House without confidence in it. There is nothing more important than health and, frankly, it sits extremely uncomfortably with me that over many decades we have not taken action when we should have done. I again thank the right hon. Member for Tatton and the hon. Member for Blackley and Middleton South for bringing this issue to the House. I urge Members not to give up this fight, and to fight for those families.

    View contribution permalink →

  16. Dr Simon Opher (Stroud) (Lab)Labour

    Good morning, Sir John. I thank the right hon. Member for Tatton (Esther McVey) for securing the debate. Although there have been serious allegations about the MHRA and vaccines, I want to commend the enormous number of NHS staff who delivered the covid vaccine programme, which saved hundreds of thousands of lives—particularly those of older people. I do not want them to be denigrated by our debate. I want to focus on the role of the MHRA with regard to antidepressants. I am the chair of the beyond pills all-party parliamentary group, and I chair our expert working group on antidepressant prescribing strategy. In particular, we want to highlight the problems associated with prescribed dependence-forming drugs such as antidepressants and the relevance of non-drug alternatives, such as social prescribing, talking therapies and access to nature. Although antidepressants may help some people, overmedicalisation is a key concern. According to the latest figures, about 9.1 million people in England alone are on antidepressants and, shockingly, 187,000 patients under 19 were prescribed antidepressants in the last year. I am a GP with 30 years’ experience, and I specialise in mental health. I know that a significant number of patients are prescribed antidepressants when in fact they are feeling completely normal emotions in response to difficult life situations. They are not suffering from a medical condition and do not, in the main, need drug treatment. The rising number of antidepressants prescribed brings up the issue of informed consent. Patients must be given clear information about the benefits and risks of antidepressants so that they can make a truly informed decision with their doctor about whether they want to take the drugs. That is where the MHRA comes in. We want to work constructively with the MHRA. I commend it on its recent initiatives recognising the need to strengthen the communication of risk around suicidality and sexual dysfunction with antidepressants. It should support the process of shared decision making between doctors and patients. We also welcome the MHRA’s patient and public involvement and engagement plan, published on 5 November, which will take into account the lived experience of patients and carers in decision making. However, the MHRA needs to do that in other areas too, and there are still areas where we would like the risks to be communicated better, including akathisia—a distressing condition of such intense mental and physical disorder that people often say they want to take their own lives. Another key issue is that patients are invariably not informed that they have an average chance of only one in eight that antidepressants will benefit their mental health.

    View contribution permalink →

  17. Jim ShannonDemocratic Unionist Party

    One issue I am aware of in my constituency and across the United Kingdom is antidepressant drugs becoming addictive, which has a negative effect on people’s mental health, as the hon. Gentleman mentioned. When the Minister responds, perhaps he could give us some indication of how Government can address the issue of those who become addicted to the prescription medication they take daily.

    View contribution permalink →

  18. Dr OpherLabour

    That is indeed an enormous problem. They say that about 2.5 million people are trying to get off antidepressants, but patients are not informed of these issues.

    View contribution permalink →

  19. Esther McVeyConservative

    The hon. Member is making a significant speech. One of my constituents on a selective serotonin reuptake inhibitor antidepressant committed suicide. Does he agree with me about the delays at the MHRA? There was significant evidence over a prolonged period of time that people on antidepressants could commit suicide when they come off, and yet nothing was done.

    View contribution permalink →

  20. Dr OpherLabour

    That is absolutely true. There are higher risks of suicide when someone starts antidepressants and when they try to come off them, and patients are rarely informed about that. That is why we want more information from the MHRA in the pill packets. Although we do not really know how antidepressants work, one accepted effect is that they dull emotions, which is called emotional blunting or numbness. That may be welcome for some, but for others it is profoundly distressing. Patient information leaflets might list effects such as apathy, indifference and lack of emotion or attachment, but patients have contacted the APPG to say that those terms do not convey the blunting of positive feelings as well as the negative ones. One male patient in his 60s recently described the emotional blunting effect of his long-term antidepressants as “suppressed love, joy, optimism, hope and creativity”. He therefore decided to stop taking them, but like many others he suffered distressing and protracted withdrawal symptoms, with little support from his GP. There is now another MHRA review into how well risks associated with withdrawals from antidepressants are communicated. Research suggests that between 34% and 50% of patients who try to come off them, as the right hon. Member for Tatton said, may experience quite severe withdrawal effects. Some 15% of patients who are long-term users—meaning they have used the drugs for more than a year—are likely to have severe withdrawal effects, and yet many of the drug companies do not accept that these drugs are addictive. Since 2022, the National Institute for Health and Care Excellence has recognised that, for the patients most at risk of experiencing withdrawal, dosages need to be reduced in a slow, stepwise fashion called hyperbolic tapering. We call on the MHRA to urgently consider the need for licensing smaller doses of existing antidepressant drugs to enable that safer deprescribing. Currently, liquid antidepressants can be used, but they are off-label and incredibly expensive, which disincentivises GPs from prescribing them. It is also difficult to dilute them and get the correct dosage. We therefore need the MHRA to force drug companies to make smaller doses of tablets. This is a tricky situation because antidepressants are licensed to treat indications such as depression, not for deprescribing. That means that very small doses of antidepressants cannot currently be created in tablet form under licence. Compounding pharmacies can make up little tablets, but they are unlicensed and cannot be routinely prescribed. A solution is urgently needed for licensing small doses of these drugs. Drug manufacturers should also be required to provide doses suitable for deprescribing for all new psychotropic drugs that will be licensed in the future. I hope the MHRA will seriously consider and act on those points. As an addendum, I would be interested in the Minister’s view on the role of the MHRA in the regulation of AI in the NHS. As chair of the all-party parliamentary health group, I am chairing a meeting later to discuss the 44 recommendations that have recently been put forward.

    View contribution permalink →

  21. Jim Shannon (Strangford) (DUP)Democratic Unionist Party

    It is a pleasure to serve under your chairship, Sir John. I thank the right hon. Member for Tatton (Esther McVey) and the hon. Member for Blackley and Middleton South (Graham Stringer) for securing the debate. It is always good to see the Minister in his place; last night he did an Adjournment debate, and this morning he is doing a Westminster Hall debate, so he and I travel similar roads, although he is the man with all the responsibility. I want to speak about the performance of the MHRA in relation to a slightly different subject—the accessibility of medications—and it is important that I put it on the record. The regulatory agency does important work—I will make this case very clearly—in ensuring that our medical treatments meet the appropriate standards of safety, quality and effectiveness, and we must give it some credit. However, approved medicines cannot be effective if patients cannot access them in the first place. There are currently widespread shortages across the United Kingdom—that is a fact of life. The National Pharmacy Association, which represents about 6,000 independent community pharmacies, states that 96% of pharmacies feel that current shortages pose a serious risk to the safety of patients. I have that very issue of access to medicines in my constituency. I will give a personal example, and then a couple of examples of others whose health has been detrimentally affected by the shortage of medications. About six weeks ago, I was diagnosed with glaucoma, but the great thing is that people can take drops in their eyes to stop the condition getting any worse. However, access to those drops is difficult to achieve in parts of Northern Ireland, and they have to be ordered in advance and in excess to carry over. That is an example of where things go wrong. In recent months, there have been record shortages of commonly dispensed medicines such as painkillers and blood pressure and epilepsy medication. I have constituents who have difficulty accessing medicines, and there are serious shortage protocols in place for hormone replacement therapy treatments and Creon—a drug to help those with pancreatic cancer or cystic fibrosis digest food, just so they can have a normal quality of life. It is clear that these shortages are not discriminatory: they affect the mildly ill to the most seriously ill, and any one of us could be affected. The shortages have come alongside increased reports of pharmacy teams facing abuse or anger from patients whose prescribed medicine is unavailable. That is of course unacceptable on all occasions and under any circumstances, but it makes it clear that frontline pharmacists are also paying a price for medicine shortages and chronic underfunding. The Minister is always very responsive to our questions, and I know that he sets out to try to help us and that he has regular conversations with the relevant Minister back home, so what discussions has he had with them to address the acute shortages in Northern Ireland? This is a UK-wide issue, but the situation is particularly precarious in Northern Ireland due to its small market and additional logistical costs. There are concerns that, due to Brexit, Northern Ireland has become a lower-priority market for medicine wholesalers, and the worry is that that will have serious implications for patient safety. I understand that the drug companies have to make money—that is their purpose, and if they do not, they cannot be in profit or deliver the medicines—but consideration has to be given to us in Northern Ireland, where the problems are particularly difficult. Recently, a constituent came to me and made a very moving appeal for these shortages to be urgently addressed. This honourable, lovely, very happy lady has great disablement: she has multiple sclerosis, and has been on the drug Nabilone for 17 years to manage her pain. Just last month, she ran out of that medication and was forced to spend two weeks in bed due to a disruption in supply. That demonstrates the real human cost of medicine shortages: every pill missed is not just a missed dose; it is a lifeline lost. We in this House need to be aware of that.

    View contribution permalink →

  22. Chris Murray (Edinburgh East and Musselburgh) (Lab)Labour

    The hon. Gentleman is speaking very movingly about a discussion with his constituent. I recently visited a constituent who underwent a mesh implant for pelvic floor prolapse in 2011, and I have written to the Minister about it. She was a young woman, and it resulted in her being unable to have children and leaving her job.

    View contribution permalink →

  23. Jim ShannonDemocratic Unionist Party

    I certainly agree, and I hope the Minister will reply to the hon. Gentleman. The mesh issue is important for women, but I have also seen men in my constituency who have had mesh, and it has affected their lives—sometimes that is lost in these debates. When we address these issues for ladies, it is important that we address them for men as well. I call on the Government to ensure that medicines remain equally available across the United Kingdom and are regulated with consistency. People in Northern Ireland who are facing the same health problems as people across the water should not be, and cannot afford to be, disadvantaged.

    View contribution permalink →

  24. Carla Lockhart (Upper Bann) (Ind)Independent

    The hon. Member is making a powerful speech. Does he agree that it is absolutely wrong that there is no independence in the MHRA? The industry is effectively marking its own homework because, ultimately, the MHRA is funded by big pharma. Does he agree that that damages trust? The Patient Safety Commissioner, whose role is to be a voice for patients, is also now hosted within the MHRA. Does he agree that that is just wrong and that we need to see change?

    View contribution permalink →

  25. Jim ShannonDemocratic Unionist Party

    I certainly do. I thank the hon. Lady for adding to the debate with those details. She is right to outline and underline those points. I saw a wee story in the paper this morning. Sometimes things happen that are good news, and the good news this morning was for those on medicinal cannabis—I have constituents who are. Medicinal cannabis controls epilepsy and other acute medical conditions, and I read that Boots will prescribe it on a video call. That is a first for pharmacies, and an example of what can be done through good working relationships between chemists and those seeking help with physical problems. The trend in medicine shortages is worsening, and increasing numbers of people will inevitably be affected. It is often said that health is not valued until sickness comes. Sadly, for many, medicine shortages are now forcing them to confront that grim reality. I look forward to the Minister’s response; he always gives us some encouragement, and I hope today to hear some encouragement for my constituents.

    View contribution permalink →

  26. Sir John Hayes (in the Chair)Conservative

    I will start the winding-up speeches at 10.35 am. I call Sir Christopher Chope.

    View contribution permalink →

  27. Sir Christopher Chope (Christchurch) (Con)Conservative

    Thank you for encouraging me to participate in the debate, Sir John. I have a few points in addition to those I made in my intervention. The failure of the MHRA is directly contributing to a decline in vaccine confidence in this country. We know that a large number of families fail to have their young children vaccinated with the measles, mumps and rubella vaccine because they do not trust the authorities. Why not? Largely because, if they look at the literature, they know that there have been too many occasions when the MHRA has failed to be wholly honest and truthful about the impact of vaccines on individuals. I was looking at the potential cause and how we might rectify it. Regulation 58 of the Human Medicines Regulations 2012 requires that “the positive therapeutic effects” of a vaccine should “outweigh the risks to the health of patients or of the public”. I do not think that is enough. What people want is some assurance that there is no risk of death or serious injury as a result of taking those vaccines. That is palpably not what is said at the moment by the MHRA, even in relation to MMR vaccines, although I am not aware of any case where an MMR vaccine has resulted in a death or serious injury. If we had that as the test, it would be a much stronger one. Although a lot of the covid-19 vaccines would have failed that test, people would have been alerted to it and they could then have weighed up in their own minds the merits or demerits of taking those vaccines, in the same way that they weigh up whether all the pressures of a Labour Government should force them to take antidepressants or not. That is a decision that they can make themselves on the basis of the evidence. I must make a declaration, Sir John, that I have not yet been driven to taking anti-depressants, despite this ghastly Government. Being serious, let us change the rules so that it is much clearer that the MHRA looks primarily at the risk of serious injury or death, rather than these weasel words of positive therapeutic effects outweighing the risks to the health of patients or the public.

    View contribution permalink →

  28. Sir John Hayes (in the Chair)Conservative

    I call the Liberal Democrat spokesman.

    View contribution permalink →

  29. Anna Sabine (Frome and East Somerset) (LD)Liberal Democrat

    It is a pleasure to serve under your chairmanship, Sir John. I thank the right hon. Member for Tatton (Esther McVey) for bringing forward this debate; I know she feels very strongly about this issue, as do many of the rest of us here. One of the first emails I received when I became an MP was from a constituent whose stepson is a victim of the Primodos scandal. Primodos was a hormonal pregnancy test and the scandal around its use is often called the forgotten thalidomide. Taking it in early pregnancy caused limb defects, congenital heart defects, developmental and learning problems, as well as stillbirths and miscarriages. My constituent, and others like her whom I have met since, have told me about the decades of fighting by families and amazing campaigners such as Marie Lyon to receive the justice they deserve for a scandal that has impacted so many lives. Unfortunately, their story is not unique. Primodos, vaginal mesh and the faulty drugs and devices examined by the Cumberlege review: in each case, patients—women—raised concerns and the system, including the MHRA, has not listened. This should be evidence enough that the MHRA needs substantial reform, yet, as we have heard this morning we are still waiting to see many vital changes. At the moment, patients are being failed by the MHRA in two ways: failed when the regulator is too slow to deliver promising treatments, and failed when it is too slow to listen when something goes wrong. The Liberal Democrats want a regulator that does both things well. This is why we are calling for reform to make it both effective and trusted. On the question of speed, there has recently been a welcome turnaround in the MHRA. After years of neglect under the previous Government, nearly all national medicine licence applications in 2025-26 were decided within the statutory 210-day limit. Credit is due here, but that statutory timeline remains too slow. In the UK, it takes an average of 322 days—nearly a year—for a new medicine or medical technology to reach patients, compared with 158 days in Germany. For someone with a rare disease or an aggressive cancer, a promising treatment stuck in a queue uses up time they may not have. Clinical trial targets are also being missed. What is the Government’s plan to improve that? The Liberal Democrats are clear that we would invest in MHRA capacity with the aim of halving the time it takes for new treatments for illnesses such as cancer to reach patients. We would make timeframes more predictable and offer more informal scientific advice from the outset, so that companies can get their products to patients sooner. On the second question, trust, the Liberal Democrats would fully implement the Cumberlege recommendations, including providing compensation for those failed by faulty drugs and devices. That should include Primodos. Finally, I turn to the subject of children with severe drug-resistant epilepsy, such as my constituent Clover, whose case I have raised in this place many times. Families like hers have been fighting for years for medicines that work. Right now, only one cannabis-based medicine is licenced for epilepsy in this country and only for three specific syndromes. Many children whose seizures have finally been brought under control depend on whole-plant medicines that remain unlicensed, so their parents are forced to pay thousands of pounds privately to keep their children alive. Organisations such as the Medcan Family Foundation have been clear about the way forward. The medicines need to be licensed more widely, and the trials that would build that evidence should sit with the MHRA. Ministers say that a licence cannot come without the evidence, but the evidence cannot come without trials that are properly designed, adaptive and up and running. Families have been caught in that loop for far too long. I should say that the Minister’s predecessor met Clover’s family and was incredibly helpful, but he was the eighth Minister they have met in the time they have been campaigning and they feel that they are being passed from pillar to post. The danger is now sharper than ever. Since Bedrocan went bankrupt last month, parents have been left wondering whether the medicine keeping their child alive will even be there in six months’ time. Will the MHRA take ownership of this situation, set out a clear route to licensing and ensure that no child is put at risk because the regulatory system has not kept pace? More generally, will the Government commit to improving MHRA’s capacity, so that it can approve licences quickly, support clinical trials and, more importantly, serve the patients that benefit most from medical innovation? My constituents and thousands of people across the country have waited decades for the MHRA to listen and improve. I hope the Minister will agree to deliver for all the victims of medical scandals.

    View contribution permalink →

  30. Sir John Hayes (in the Chair)Conservative

    I call the Conservative spokesman.

    View contribution permalink →

  31. Dr Caroline Johnson (Sleaford and North Hykeham) (Con)Conservative

    It is a pleasure to serve under your chairmanship, Sir John. I congratulate my right hon. Friend the Member for Tatton (Esther McVey) and the hon. Member for Blackley and Middleton South (Graham Stringer) on securing this important debate. I need to declare some interests: I am an NHS consultant paediatrician and a member of the Royal College of Paediatrics and Child Health and of the British Medical Association, and I worked as a volunteer vaccinator in the covid scheme for much of the pandemic. The Medicines and Healthcare Products Regulatory Agency is there to ensure that our medicines are safe and effective. It is an important organisation, but it is also an executive agency of the Department of Health and Social Care and, ultimately, Government Ministers are responsible for what goes on. As we have heard, numerous concerns have been raised. I will make a couple of general comments and then review a couple of specific cases. First, the yellow card scheme is important for safety monitoring. Awareness of the scheme has increased since the pandemic; reports went up 75% between 2020 and 2022. Can the Minister confirm that the MHRA has the resources to manage that increase in reports and is able to look at them effectively to make sure that nothing is missed? Many hon. Members mentioned the vaccine damage payment. People left severely disabled by an adverse reaction to a vaccine may be able to claim through the scheme. Since 2022, £32 million has been paid out in compensation, with £83 million in administration costs. Is the Minister on top of those costs? Is he happy that the costs are proportional to the administration being provided? The Government have repeatedly said that they are assessing options to improve the scheme. Can the Minister enlighten us on what those options are and when the Government plan to make a decision? My confidence in the MHRA was eroded further following a debate in May 2025 on what should have been a very straightforward statutory instrument, which set the agency’s fees. When looking at the sums, a civil service pay rise of 2.2% was assumed, which was below inflation; the Minister could not tell us whether it was the intention of the Government to provide a below-inflation pay rise, which in the end they did not. The agency failed to add the Government’s own rise in national insurance, and the Minister could not tell us whether or not it needed to be applied, which it did. That left the agency about 15% out in its sums. Given that it works on a cost recovery basis, the Minister insisted that it could manage—but, if that were the case, why was it asking for more money than it needed? In practice, it did not have enough, because it came back for more money just months later. The Minister needs to ensure that he has a grip not just on what the agency is doing medically, but on whether its sums are right, because ultimately it is important for all of us to get good medication. Moving on to specific cases, I want to look at the puberty blockers trial. One of the key roles of the MHRA is in regulating and approving clinical trials. The puberty blockers trial will include 226 children—226 physically healthy children, who are developing normally from a pubertal point of view. They are going to be given powerful drugs that could cause them potentially serious damage. The trial has been discussed in detail on the Floor of the House, but I want to look specifically at the MHRA’s role. After the trial was approved, Professor Jacob George was appointed as the chief medical and scientific officer of the MHRA in January. In February, a redacted letter was produced, talking about concerns related to the wellbeing of participants. At first, the Government appeared not to heed that warning. The following month, Professor George recused himself from further discussion. It was not clear why, but it led to concerns in the press that it was due to his gender-critical views, which are, of course, protected views under the Equality Act 2010. Could the Minister shed further light on what happened? In June, it was decided that a minimum age would be set of 11 for girls and 12 for boys. Some people asked me, “Why are those different?”. The ages are different because girls go into puberty earlier than boys—an ironic recognition of biology in a trial that otherwise believes that girls may be able to be boys. However, the MHRA recommended a minimum age of 14. Could the Minister explain why there is a difference? The MHRA said that the minimum age was there to strengthen safeguards and ensure the monitoring of safety, bone health and cognition. Why have the Government chosen to have a minimum age of 11 or 12—in some cases, primary school children—rather than 14? I appreciate the Minister has been in the role for only a few months, but is he content to be responsible for the trial? Is he—as the previous Secretary of State said they would—receiving monthly updates on the trial’s progress? I want to ask about the Hughes Report, published in February 2024. Members are familiar with the details of this scandal. We do not have exact numbers, but we know that around 10,000 women were affected by pelvic mesh and around 20,000 children were born disabled after exposure to sodium valproate in the womb. Earlier this month, a documentary called “Mums v Big Pharma” focused on Janet and Emma, two mums to children affected by intrauterine exposure to sodium valproate. I was fortunate to meet Janet and Emma recently to hear about their campaign. They did not know that these drugs were going to harm their children, but they have evidence that shows the Government knew that it might. They are inspiring women, and I pay tribute to them and their campaign. It is now approaching three years since this report, and what have the Government done? As far as I can see, nothing. The last Labour Prime Minister failed to act; the latest Labour Prime Minister raised hopes with his words, but has so far dashed them with his lack of action. Last month, the Minister for Patient Safety said “a decision has not yet been taken to provide financial redress,” —[ Official Report , 29 October 2026; Vol. 792, c. 552.] so when will the Government respond to the Hughes Report and when will that decision be made? That Minister also said that the foetal exposure to medicines pilot service in hospitals in Manchester and Newcastle will be extended. These are run by NHS England, which the Government are abolishing. Will this extension still happen? If so, can the Minister confirm who will be responsible for it? In summary, there are concerns about the MHRA’s ability to respond to concerns raised, to act quickly, to improve medicines and to manage the financial adding-up. The Minister has only been in post for a few months, but he is a clever man and I know he is concerned to do well; I am sure he has identified the problems, but will he act? This Government have a tendency to kick the can down the road. There is no workforce plan and there are endless delays to plans for maternity. I know you, Sir John, are particularly interested in the acquired brain injury plan; that has also been further delayed, having been promised for last December. Warm words are cold comfort when they do not come with action. Can the Minister reassure the House that he—as a new Minister, whom I welcome to his position and am glad to see there—will act promptly?

    View contribution permalink →

  32. Sir John Hayes (in the Chair)Conservative

    I now call on James Frith. Minister, please allow a few moments at the end for the right hon. Lady to wind-up. In turn, the right hon. Lady will allow a moment for me to move the motion.

    View contribution permalink →

  33. The Parliamentary Under-Secretary of State for Health and Social Care (Mr James Frith)Labour

    It is a pleasure to serve with you in the Chair, Sir John. I am very grateful to the right hon. Member for Tatton (Esther McVey) and my hon. Friend the Member for Blackley and Middleton South (Graham Stringer) for securing today’s debate. I am also grateful to all Members who have contributed to, not only today’s debate, but this great history of debates on such incredible issues and related injustices. The exhaustion that some of these families continue to live with is a result of some dark decades of misinformation and withheld or incorrect information. I am happy to stand here as a Government Minister accountable to this House, and responsible for holding feet to the fire with the MHRA. I take that responsibility very seriously. I am reminded of the very powerful phrase that Bishop James Jones used in his report on the Hillsborough inquiry, the “patronising disposition of unaccountable power”. That is something that speaks to my instincts and my political DNA. It is absolutely right that our systems hold Members like me responsible for the threat, the possibility and the prospect of that patronising disposition of unaccountable power. I will come on to speak about how I am assured of significant progress being made, but at no point do I deny, defer or dismiss the serious difficulties those families have been through.

    View contribution permalink →

  34. Tessa Munt (Wells and Mendip Hills) (LD)Liberal Democrat

    Will the Minister give way?

    View contribution permalink →

  35. Mr FrithLabour

    I will make some progress before I take interventions shortly. The issues we have discussed matter enormously. Medicines and medical devices affect us all, often when we are at our most vulnerable. The public must be able to trust the system that regulates those medicines and devices. It must be rigorous, independent and transparent and, when concerns are raised, they must be heard. I acknowledge that the experiences of patients and families that hon. Members have raised remain deeply difficult. Good regulation requires us not simply to explain the system but to listen carefully when people raise concerns and issues. I keep in mind Bev in my constituency of Bury, who lives daily with the effects of pelvic mesh and the complete destruction of her physical relationship, which she wanted me to convey. I think of Janet and Emma, also from Bury, and their incredible sodium valproate campaign, and all the testimony we have heard today. Regulation needs to occur regularly, not as a one-off event. It needs to be in a permanent state of review, as does the review of the regulator itself. The MHRA has a critical responsibility; its fundamental purpose is to protect the public by ensuring that medicines and devices meet appropriate standards of safety, quality, performance and effectiveness. It must do that independently, based on the best available evidence. Regarding independence, as referred to by the right hon. Member for East Antrim (Sammy Wilson), fees are payable regardless of the outcome of an application, and are designed to recover the cost of providing the regulatory service, rather than generate a profit. Though subject to scrutiny and the need to be robust, that model is the right one, consistent with global regulators. The hon. Member for Strangford (Jim Shannon) asked about my contact with Northern Ireland. I have two dates in January and February to visit Northern Ireland, in my first few months in this role. I am happy to pre-meet him for a discussion and will be sure to pick up the issue with counterparts in Northern Ireland. Some hon. Members asked whether reporting by healthcare professionals should be mandatory. Manufacturers already have statutory reporting obligations, while professional guidance provides for healthcare professionals to act on safety concerns. There is currently limited evidence that making it mandatory for healthcare professionals to report would improve the ability to detect signs of possible safety problems. I am conscious that that sounds like a denial or dismissal, but my assessment of the model is that what we actually need is much more access to patients and that patients need access to the system. At the moment, it is effectively a business-to-business or organisation-to-organisation model, and the patient is not in the loop. One of my responsibilities in health innovation, around the new iterations of the NHS app and the development of NHS Digital, is to ensure verified information, so as to lance the disinformation about the efficacy of vaccines the hon. Member for Christchurch (Sir Christopher Chope) mentioned. Patients need to be able to speak to the system more effectively. The NHS app development I am overseeing is beginning to have that thought; I spoke this morning to the MHRA about leaning more into that. That should not be interpreted as complacency about under-reporting. The MHRA is improving connections between yellow card and clinical systems, working with healthcare partners to increase reporting, making it easier to use, and developing its capability to use data and analytics to identify emerging risks earlier. I will say more on the yellow card system later. I note that there has been a significant improvement in the MHRA’s operational performance in the past 18 months, thanks to Government funding and appropriate resource. A question was posed about whether there is enough resource and funding. When 99% of national medicines licence applications were determined on time and 97% of clinical trials and investigations assessed within target, I believe the answer is yes. Lord O’Shaughnessy agrees: his independent review highlighting the significant challenges facing the clinical trials environment described the MHRA’s progress on performance since then as “remarkable”. On the matter of clinical trials, we have just confirmed the movement from 153 days to 100 days for launching clinical trials, with an appetite to go further and faster. That is an important point in answer to the issues raised about accessing clinical trials, freedom to engage with clinical trials and the pathway to market for the drugs and trial successes in question. I commit to writing to the Opposition spokesperson, the hon. Member for Sleaford and North Hykeham (Dr Johnson), about the issue of vaccine damage payments. On the matter of puberty blockers that she raised, I recognise her concerns, and hon. Members have rightly highlighted the role of the MHRA in strengthening safeguards. However, I remind hon. Members that a judicial review concluded in July 2026 and the High Court rejected challenges to the regulatory decisions made in the assessment of the pathways trial, stating that: “The MHRA is responsible for the safety of the clinical trial and the safeguarding of participants. It undertook a rigorous process to assess the trial before giving its initial approval in…2025.” Crucially, that performance extends to safety monitoring, with the MHRA continuing to exceed its targets for processing serious adverse incident reports within 24 hours. That shows it is a fast and responsive regulator that can collaborate with the wider system and take action to protect patients when potential risks are identified.

    View contribution permalink →

  36. Tessa MuntLiberal Democrat

    The Minister is talking about scientific studies and trials, and in relation to Primodos in particular new scientific studies are being conducted. But I do not understand—maybe the Minister can explain it to me—how the MHRA is able to justify withholding vital information requested through freedom of information requests. Those requests have been made, but the Department has either redacted or refused to release data that is required for those studies to go ahead. He speaks about transparency; can he improve transparency in that respect?

    View contribution permalink →

  37. Mr FrithLabour

    I am happy to improve transparency and remain accountable to the House on this issue. The MHRA and the Commission on Human Medicines are committed to considering new and relevant scientific information, including recently published material identified in this debate. I will happily pick that up with the hon. Lady shortly. Performance cannot be measure by speed alone. Today, hon. Members have rightly asked equally important questions about whether the regulator identifies safety signals robustly enough, acts on them appropriately, is sufficiently transparent abouts its decisions, and listens properly to patients. I want to address those questions directly. We have to be careful not to talk about innovation as though it cancels out the testimonies that Members have made behalf of their constituents today, because it does not. Behind Primodos, sodium valproate, pelvic mesh and other cases are people whose families believed that the system was supposed to protect them. I am sympathetic to the point of the hon. Member for Lagan Valley (Sorcha Eastwood) about there being both a class and a gender lens to this issue, and I have had conversations about that with regard to the application of the women’s health strategy. Hon. Members will also have heard the Minister for Women and Equalities make that class point passionately. I am happy to pick up on that matter subsequently. We should acknowledge that those experiences are completely unacceptable. Trust cannot be demanded from those who feel that they have been let down; it has to be earned anew and permanently renewed. I recognise the argument recently made in this House that for affected families, preventing future harm does not resolve the consequences of the harm that they have already experienced. On the redress scheme, the Minister for Public Health and Patient Safety said to the House last month that we are “committed to making meaningful progress in this Parliament”. —[ Official Report , 20 October 2026; Vol. 791, c. 956.] I will not pre-empt that work today, but the Prime Minister has spoken of his alertness to the issue.

    View contribution permalink →

  38. Dr Caroline JohnsonConservative

    Will the Minister give way?

    View contribution permalink →

  39. Mr FrithLabour

    I will make some progress. I am conscious that I need to give the right hon. Member for Tatton time to sum up. We should not assume that the regulator of today is incapable of learning from the regulator of the past. The test that I would apply is whether it listens when patients raise concerns and whether it shows a readiness to reform or renew. That matters for the future as much for the past. Science does not stand still while institutions catch up. New medicines and devices, and AI—which the good doctor, my hon. Friend the Member for Stroud (Dr Opher), referred to—are being introduced. My view is that innovation moves at the speed of trust. Good regulation should therefore be an enabler, not by lowering the bar, but by making the bar clear, rigorous and responsive to evidence. My hon. Friend is right that the Government accepted the 44 recommendations and will be responding formally with a plan for delivery. As he helpfully confirmed, the patient and public involvement and engagement plan is about giving patients much more information about the professional dialogue that happens around prescription. It also speaks to the wider point about the NHS app and about the digital verified information that we make available so that people can make informed decisions. Hon. Members raised concerns about the number of fatal covid vaccine reports that were investigated. The MHRA assesses every yellow card report involving a suspected adverse reaction with a fatal outcome. That includes all fatal covid vaccine reports. The MHRA should be judged on whether it can both learn honestly from where regulation has fallen short and give patients the confidence to benefit from where science takes us next. The hon. Member for Frome and East Somerset (Anna Sabine) talked about clinical trials, and she also raised Bedrocan. Through the British embassy in The Hague, I am in active discussions about the bankruptcy of the company and about suitable alternatives, but I am conscious that there can be significant consequences if people with epilepsy switch medication, and I am sensitive to that. A regulator succeeds ultimately because patients, their healthcare providers and the public have confidence in the quality and independence of its decisions. That is the standard that the Government expect from the MHRA, and we will continue to hold it to that standard. I again thank the right hon. Member for Tatton, my hon. Friend the Member for Blackley and Middleton South and all those who have contributed to this important debate.

    View contribution permalink →

  40. Esther McVeyConservative

    I thank all Members who ensured that this debate happened and who spoke about the performance and failure of the MHRA, prompted by what happened to their constituents. Time and again—not just today but over a long period—hon. Members have come to the House to raise concerns about the agency’s repeated failures and delays, and about the lack of transparency, independence, trust, teeth, oversight and scrutiny. It is time that action is taken. How many more times do hon. Members have to secure a debate, come to the House and point out the failures? I hope that all hon. Members here today have a further meeting with the Minister to ensure that he really does take the issue seriously. We do not want to be back here again talking about Primodos, surgical mesh, sodium valproate, the covid vaccines, antidepressants, the yellow card scheme, thalidomide and puberty blockers.

    View contribution permalink →

  41. Mr FrithLabour

    It was remiss of me not to answer the right hon. Lady’s question. I am happy to meet if the diary works for the planned date—otherwise a subsequent one will be found. I am very happy to give that commitment.

    View contribution permalink →

  42. Esther McVeyConservative

    I thank the Minister for that commitment. What the public want is an organisation that can be relied upon to be in charge of the safety and efficacy of medicines and medical devices. As it stands, it cannot be. Motion lapsed (Standing Order No. 10(6)).

    View contribution permalink →

Source: UK Parliament Hansard API. Debate ID: 5439288.